KR20230169182A - 신규한 DARPin 기반 CD70 인게이저 - Google Patents

신규한 DARPin 기반 CD70 인게이저 Download PDF

Info

Publication number
KR20230169182A
KR20230169182A KR1020237036653A KR20237036653A KR20230169182A KR 20230169182 A KR20230169182 A KR 20230169182A KR 1020237036653 A KR1020237036653 A KR 1020237036653A KR 20237036653 A KR20237036653 A KR 20237036653A KR 20230169182 A KR20230169182 A KR 20230169182A
Authority
KR
South Korea
Prior art keywords
ala
leu
gly
asp
ankyrin repeat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237036653A
Other languages
English (en)
Korean (ko)
Inventor
크리스티안 라이헨
니나 레쉬케
베른트 슐러레트
Original Assignee
몰리큘라 파트너스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 몰리큘라 파트너스 아게 filed Critical 몰리큘라 파트너스 아게
Publication of KR20230169182A publication Critical patent/KR20230169182A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Lock And Its Accessories (AREA)
  • Ignition Installations For Internal Combustion Engines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237036653A 2021-04-09 2022-04-07 신규한 DARPin 기반 CD70 인게이저 Pending KR20230169182A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173186P 2021-04-09 2021-04-09
US202163172973P 2021-04-09 2021-04-09
US63/172,973 2021-04-09
US63/173,186 2021-04-09
US202163265181P 2021-12-09 2021-12-09
US63/265,181 2021-12-09
PCT/IB2022/053275 WO2022215032A1 (en) 2021-04-09 2022-04-07 Novel darpin based cd70 engagers

Publications (1)

Publication Number Publication Date
KR20230169182A true KR20230169182A (ko) 2023-12-15

Family

ID=81386901

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237036653A Pending KR20230169182A (ko) 2021-04-09 2022-04-07 신규한 DARPin 기반 CD70 인게이저

Country Status (9)

Country Link
US (1) US20250074994A1 (https=)
EP (1) EP4319883A1 (https=)
JP (1) JP2024513559A (https=)
KR (1) KR20230169182A (https=)
AU (1) AU2022252985A1 (https=)
BR (1) BR112023020685A2 (https=)
CA (1) CA3214020A1 (https=)
MX (1) MX2023011978A (https=)
WO (1) WO2022215032A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
EP4724460A1 (en) * 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd16a binding proteins and their use
EP4724486A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd2 binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
PL2643349T3 (pl) * 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
AU2014317009A1 (en) * 2013-09-05 2016-03-10 Aduro Biotech Holdings, Europe B.V. CD70-binding peptides and method, process and use relating thereto
KR102427117B1 (ko) * 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
PE20210708A1 (es) * 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
KR20260046525A (ko) * 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
CN114222757A (zh) * 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
WO2020245746A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins

Also Published As

Publication number Publication date
JP2024513559A (ja) 2024-03-26
MX2023011978A (es) 2023-11-17
CA3214020A1 (en) 2022-10-13
BR112023020685A2 (pt) 2023-12-12
WO2022215032A1 (en) 2022-10-13
AU2022252985A1 (en) 2023-11-16
US20250074994A1 (en) 2025-03-06
EP4319883A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
JP6976335B2 (ja) 組み換え結合タンパク質及びその使用
US20250074994A1 (en) Novel darpin based cd70 engagers
US20240150475A1 (en) Novel darpin based cd123 engagers
KR102290592B1 (ko) Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질
US20240317852A1 (en) Novel darpin based cd33 engagers
CN107636014A (zh) 抗癌融合多肽
JP2023528207A (ja) 組換えｃｄ４０結合タンパク質及びそれらの使用
US11834504B2 (en) DARPin based multi-specific t-cell engagers
JP2023554379A (ja) 組換えｃｄ３結合タンパク質及びそれらの使用
WO2024251628A1 (en) Recombinant cd16a binding proteins and their use
WO2024251695A1 (en) Recombinant cd47 binding proteins and their use
CN117242100A (zh) 基于DARPin的新型CD70接合物
CN117255803A (zh) 基于DARPin的新型CD33接合物
CN117177996A (zh) 基于DARPin的新型CD123接合物
CN116802213A (zh) 重组cd3结合蛋白及其用途
CN121263440A (zh) 重组cd2结合蛋白及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250317

Comment text: Request for Examination of Application